|
Volumn 125, Issue 3, 2000, Pages 617-634
|
Modelling rubella in Europe
a b c a |
Author keywords
[No Author keywords available]
|
Indexed keywords
MEASLES MUMPS RUBELLA VACCINE;
RUBELLA ANTIBODY;
RUBELLA VACCINE;
ADOLESCENT;
ADULT;
ARTICLE;
CHILD;
CHILD CARE;
CONGENITAL RUBELLA SYNDROME;
CONTROLLED STUDY;
DENMARK;
DISEASE MARKER;
DISEASE MODEL;
ENDEMIC DISEASE;
EPIDEMIC;
EUROPE;
FEMALE;
FINLAND;
GEOGRAPHIC DISTRIBUTION;
GERMANY;
HEALTH CARE POLICY;
HEALTH PROGRAM;
HUMAN;
IMMUNIZATION;
INCIDENCE;
INFANT;
INFECTION PREVENTION;
ITALY;
MAJOR CLINICAL STUDY;
MATHEMATICAL MODEL;
NETHERLANDS;
NONHUMAN;
ONSET AGE;
PREGNANCY COMPLICATION;
PREVENTIVE HEALTH SERVICE;
RUBELLA;
SEROPREVALENCE;
SOCIAL ASPECT;
UNITED KINGDOM;
VACCINATION;
VIRUS TRANSMISSION;
ADOLESCENT;
ADULT;
AGED;
CHILD;
CHILD, PRESCHOOL;
DEMOGRAPHY;
DISEASE OUTBREAKS;
EUROPE;
FEMALE;
HUMANS;
IMMUNIZATION PROGRAMS;
INFANT;
INFANT, NEWBORN;
MALE;
MIDDLE AGED;
MODELS, THEORETICAL;
PUBLIC HEALTH;
RUBELLA SYNDROME, CONGENITAL;
RUBELLA VACCINE;
SEROLOGIC TESTS;
|
EID: 0034487371
PISSN: 09502688
EISSN: None
Source Type: Journal
DOI: 10.1017/S0950268800004660 Document Type: Article |
Times cited : (61)
|
References (24)
|